Cargando…
Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
Coronavirus disease 2019 (COVID-19) has been a pandemic disease of which the termination is not yet predictable. Currently, researches to develop vaccines and treatments is going on globally to cope with this disastrous disease. Main protease (3CLpro) from severe acute respiratory syndrome coronavir...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470085/ https://www.ncbi.nlm.nih.gov/pubmed/32746637 http://dx.doi.org/10.1080/14756366.2020.1801672 |
_version_ | 1783578515449315328 |
---|---|
author | Jo, Seri Kim, Suwon Kim, Dae Yong Kim, Mi-Sun Shin, Dong Hae |
author_facet | Jo, Seri Kim, Suwon Kim, Dae Yong Kim, Mi-Sun Shin, Dong Hae |
author_sort | Jo, Seri |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) has been a pandemic disease of which the termination is not yet predictable. Currently, researches to develop vaccines and treatments is going on globally to cope with this disastrous disease. Main protease (3CLpro) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the good targets to find antiviral agents before vaccines are available. Some flavonoids are known to inhibit 3CLpro from SARS-CoV which causes SARS. Since their sequence identity is 96%, a similar approach was performed with a flavonoid library. Baicalin, herbacetin, and pectolinarin have been discovered to block the proteolytic activity of SARS-CoV-2 3CLpro. An in silico docking study showed that the binding modes of herbacetin and pectolinarin are similar to those obtained from the catalytic domain of SARS-CoV 3CLpro. However, their binding affinities are different due to the usage of whole SARS-CoV-2 3CLpro in this study. Baicalin showed an effective inhibitory activity against SARS-CoV-2 3CLpro and its docking mode is different from those of herbacetin and pectolinarin. This study suggests important scaffolds to design 3CLpro inhibitors to develop antiviral agents or health-foods and dietary supplements to cope with SARS-CoV-2. |
format | Online Article Text |
id | pubmed-7470085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-74700852020-09-15 Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro Jo, Seri Kim, Suwon Kim, Dae Yong Kim, Mi-Sun Shin, Dong Hae J Enzyme Inhib Med Chem Research Paper Coronavirus disease 2019 (COVID-19) has been a pandemic disease of which the termination is not yet predictable. Currently, researches to develop vaccines and treatments is going on globally to cope with this disastrous disease. Main protease (3CLpro) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the good targets to find antiviral agents before vaccines are available. Some flavonoids are known to inhibit 3CLpro from SARS-CoV which causes SARS. Since their sequence identity is 96%, a similar approach was performed with a flavonoid library. Baicalin, herbacetin, and pectolinarin have been discovered to block the proteolytic activity of SARS-CoV-2 3CLpro. An in silico docking study showed that the binding modes of herbacetin and pectolinarin are similar to those obtained from the catalytic domain of SARS-CoV 3CLpro. However, their binding affinities are different due to the usage of whole SARS-CoV-2 3CLpro in this study. Baicalin showed an effective inhibitory activity against SARS-CoV-2 3CLpro and its docking mode is different from those of herbacetin and pectolinarin. This study suggests important scaffolds to design 3CLpro inhibitors to develop antiviral agents or health-foods and dietary supplements to cope with SARS-CoV-2. Taylor & Francis 2020-08-04 /pmc/articles/PMC7470085/ /pubmed/32746637 http://dx.doi.org/10.1080/14756366.2020.1801672 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Jo, Seri Kim, Suwon Kim, Dae Yong Kim, Mi-Sun Shin, Dong Hae Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro |
title | Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro |
title_full | Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro |
title_fullStr | Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro |
title_full_unstemmed | Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro |
title_short | Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro |
title_sort | flavonoids with inhibitory activity against sars-cov-2 3clpro |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470085/ https://www.ncbi.nlm.nih.gov/pubmed/32746637 http://dx.doi.org/10.1080/14756366.2020.1801672 |
work_keys_str_mv | AT joseri flavonoidswithinhibitoryactivityagainstsarscov23clpro AT kimsuwon flavonoidswithinhibitoryactivityagainstsarscov23clpro AT kimdaeyong flavonoidswithinhibitoryactivityagainstsarscov23clpro AT kimmisun flavonoidswithinhibitoryactivityagainstsarscov23clpro AT shindonghae flavonoidswithinhibitoryactivityagainstsarscov23clpro |